Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy-Reference-Cited by-同舟云学术

Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy

Published:2018-12-18 Issue:1 Volume:68 Page:1-9
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Maio Michele^ORCID,Coukos George^ORCID,Ferrone Soldano^ORCID,Fox Bernard A.^ORCID,Fridman Wolf H.^ORCID,Garcia Patrick L.,Lahn Michael,Provendier Olivier,Russo Vincenzo^ORCID,Rüttinger Dominik,Shalabi Aiman,Trajanoski Zlatko^ORCID,Viallet Jean,Wolchok Jedd D.^ORCID,Ibrahim Ramy

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s00262-018-2285-y/fulltext.html

Reference47 articles.

1. Maio M, Fonsatti E (2014) The Italian network for tumor biotherapy (NIBIT): past, present and future goals. Rev Health Care 5(1):3–6

2. Russo V, Amadori A, Bregni M, Calabro L, Colombo MP, Di Nicola M, Ferrucci PF, Proietti E, Maio M, Bellone M (2017) Goals and objectives of the Italian network for tumor biotherapy (NIBIT). Cytokine Growth Factor Rev 36:1–3. https://doi.org/10.1016/j.cytogfr.2017.06.004

3. Maio M, Lofiego MF, Fazio C, Cannito S, Chiarucci C, Giacobini G, Valente M, Tunici P, Covre A, Russo V (2018) Fifteenth meeting of the network Italiano per la Bioterapia dei Tumori (NIBIT) on cancer bio-immunotherapy, Siena, Italy, October 5–7, 2017. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-018-2222-0

4. Hansen AR, Infante JR, McArthur G, Gordon MS, Lesokhin AM, Stayner A-L, Bauer TM, Sandhu S, Tsai F, Snyder A, Subramaniam DS, Kim J, Stefanich E, Li C-C, Ruppel J, Anderson M, Gilbert H, McCall B, Huseni MA, Rhee I, Pishvaian M (2016) Abstract CT097: a first-in-human phase I dose escalation study of the OX40 agonist MOXR0916 in patients with refractory solid tumors. Cancer Res 76(14 Supplement):CT097–CT097. https://doi.org/10.1158/1538-7445.am2016-ct097

5. Angevin E, Bauer TM, Ellis CE, Gan H, Hall R, Hansen A, Hoos A, Jewell RC, Katz J, Martin-Liberal J, Maio M, Mayes PA, Mazumdar J, Millward M, Rischin D, Schellens JH, Yadavilli S, Zhou H (2017) Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors. Cancer Res 77(13 Supplement):CT039–CT039. https://doi.org/10.1158/1538-7445.am2017-ct039

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?;European Journal of Cancer;2024-02

2. Immunotherapy for brain metastases and primary brain tumors;European Journal of Cancer;2023-01

3. A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation;Journal of Experimental & Clinical Cancer Research;2021-07-23

4. Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!;European Journal of Cancer;2021-07

5. Quantifying the efficacy of checkpoint inhibitors on CD8+ cytotoxic T cells for immunotherapeutic applications via single-cell interaction;Cell Death & Disease;2020-11